As of Feb 27
| -0.04 / -3.57%|
The 2 analysts offering 12-month price forecasts for Protalix Biotherapeutics Inc have a median target of 2.60, with a high estimate of 4.00 and a low estimate of 1.20. The median estimate represents a +140.74% increase from the last price of 1.08.
The current consensus among 2 polled investment analysts is to Buy stock in Protalix Biotherapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.